Neoadjuvant Toripalimab plus chemotherapy in patients with stage IIB-IIIB NSCLC: A single-center, prospective, single-arm, phase 2 trial (Renaissance Study).

作者
Shi Yan,Jinfeng Chen,Jia Wang,Chao Lv,Jiwang Bi,Xin Yang,Shaolei Li,Yuzhao Wang,Xiang Li,Yue Yang,Nan Wu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): e21128-e21128
标识
DOI:10.1200/jco.2022.40.16_suppl.e21128
摘要

e21128 Background: Neoadjuvant treatment of a programmed cell death protein 1 (PD-1) inhibitor plus chemotherapy has been shown to be promising in treating resectable non-small cell lung cancer (NSCLC). The current study aimed to investigate the efficacy and safety of toripalimab plus double platinum-based chemotherapy as neoadjuvant treatment for stage IIB-IIIB NSCLC. Methods: Study eligibility involved stage IIB-IIIB, wildtype EGFR/ALK NSCLC pts with ECOG PS 0-1 status. Pts received 2-4 cycles of toripalimab (240mg, q3w) plus cisplatin-based chemotherapy. All pts were assessed by imaging/surgical indication after the second cycle of treatment. Pts who cannot undergo surgery will be reassessed after another 1-2 cycles of neoadjuvant therapy. Primary endpoints were major pathological response (MPR), complete pathological response (pCR). Secondary endpoints were objective response rate (ORR), R0 resection rate and safety. Results: A total of 52 eligible pts (median age: 62, IQR: 45-76; female: 4, 7.7%) were enrolled and received 2-4 cycles neoadjuvant treatment since Mar 2021. 42 pts had squamous cell carcinoma and 10 pts had non-squamous cell carcinoma. Disease distribution in stage IIB, IIIA and IIIB consisted of 14, 30 and 8 pts, respectively. 15 pts were undergoing preoperative treatment or preparing for surgery, 32 pts underwent resection (median interval between neoadjuvant treatment and surgery: 67 days, IQR 39-113), 5 pts were unsuitable for surgery (1 pt had immune-related pneumonia; 2 pts who had stable disease were considered radical radiotherapy and immunotherapy for maintenance due to the difficulty of surgery induced by tumor location and lymph node metastasis; 2 pts continued toripalimab plus chemotherapy or radiotherapy due to high surgical risk induced by old age and poor performance status). 20 pts (20/32, 62.5%) achieved MPR, including 16 pts (16/32, 50%) with pCR. 6 pts (6/8, 75%), 12 pts (12/18, 66.7%), and 2 pts (2/6, 33.3%) with stage IIB, IIIA and IIIB achieved MPR respectively. R0 resection was achieved for all 32 pts (100%). 23 pts underwent surgery with cN2/N1 at baseline (23/24, 95.8%) achieved nodal downstaging. For pts who finished radiological reassessment (45 pts finished the treatment schedule and only 43 pts finished radiological reassessment), ORR was 83.7% (36/43). Grade 1-2 TRAEs were reported in 33 patients (33/45, 73.3%). Grade 3-4 TRAEs were reported in 6 pts (6/45, 13.3%). Conclusions: Toripalimab plus platinum-based doublet as neoadjuvant treatment yields a high MPR rate, manageable toxicity and feasible surgical resection in stage IIB-IIIB NSCLC. Clinical trial information: NCT04606303.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴实的哲瀚完成签到 ,获得积分20
刚刚
展望未来完成签到 ,获得积分10
2秒前
3秒前
3秒前
小白菜完成签到,获得积分10
4秒前
一个橡果完成签到,获得积分10
4秒前
6秒前
poison完成签到 ,获得积分10
6秒前
6秒前
山海不远发布了新的文献求助30
7秒前
星辰大海的应助被哈基米德采纳,获得10
9秒前
万能图书馆的应助被邱化兴采纳,获得10
9秒前
华仔的应助被Jenson采纳,获得10
10秒前
Besttin9799发布了新的文献求助30
11秒前
11秒前
科研小李发布了新的文献求助10
11秒前
深情安青的应助被smx111采纳,获得20
11秒前
11秒前
无极微光的应助被饱满南松采纳,获得20
12秒前
12秒前
Liu6868完成签到,获得积分10
13秒前
斯文败类的应助被lyy采纳,获得10
14秒前
14秒前
东都行完成签到,获得积分10
14秒前
14秒前
科研通AI6.2的应助被闯天涯采纳,获得10
15秒前
温柔发卡完成签到,获得积分10
17秒前
17秒前
17秒前
科研通AI6.3的应助被壮观雁易采纳,获得10
18秒前
18秒前
18秒前
xieburou完成签到,获得积分10
19秒前
19秒前
生性不爱说话完成签到,获得积分10
20秒前
JamesPei的应助被霁月采纳,获得10
20秒前
852的应助被霁月采纳,获得10
20秒前
ding的应助被霁月采纳,获得10
21秒前
orixero的应助被霁月采纳,获得10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500